1 / 34

University Medical Center Groningen, Groningen, The Netherlands

Volume Status and Diuretic Therapy in Systolic Heart Failure, and the Detection of Early Abnormalities in Renal and Tubular Function.

brady
Download Presentation

University Medical Center Groningen, Groningen, The Netherlands

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Volume Status and Diuretic Therapy in Systolic Heart Failure, and the Detection of Early Abnormalities in Renal and Tubular Function Kevin Damman, Marie J. Ng KamChuen, Robert J. MacFadyen, Gregory YH Lip, David Gaze, Paul O. Collinson, Hans L. Hillege, Wim van Oeveren, Adriaan A. Voors, and Dirk J. van Veldhuisen University Medical Center Groningen, Groningen, The Netherlands University of Birmingham, Birmingham, United Kingdom St George’s Hospital, London, United Kingdom

  2. Background • Renalfailure is prevalent in acute and chronicheartfailure • Renal failure is the most important predictor of outcome in patientswithheart failure • Pathophysiology of reduced glomerular filtrationrate (GFR): • Decreasedrenalbloodflow (RBF) • Increaedcentralvenouspressure (CVP) J Am Coll Cardiol 2011;57:2233-41

  3. Background Especially in situations of reduced RBF, increased CVP is associated with reduced GFR Damman et al. Eur J Heart Fail 2007

  4. Background • Higher CVP associated with lower eGFR along the whole spectrum of cardiovascular disease • CVP predicts worsening renal function (WRF) Damman et al. JACC 2009, Mullens et al. JACC 2009

  5. Background • Diuretics are the cornerstone of treatment of symptoms and signs of congestion in heart failure. • However, the efficacy of diuretics to decrease morbidity and mortality in heart failure has never been established. • Higher doses of diuretics have been associated with worsening renal function J Am Coll Cardiol 2011;57:2233-41

  6. Background High dose of IV diuretics associated with occurence of WRF Metra et al. Eur J Heart Fail 2008

  7. Background High dose of IV diuretics associated with occurence of WRF DOSE study WRF occurred significantly more in high vs low dose Diuretic regime: 23 vs 14%, P = 0.04 Felker et al. NEJM 2011

  8. Background Worsening renal function, at any point in time, is associated with poor prognosis Damman et al. Eur J Heart Fail 2009. Damman et al. J Card Fail 2007

  9. Background Tubular Damage is prevalent in Heart Failure Damman et al. Heart 2010

  10. Summary • Higher central venous pressure associated with impaired GFR, tubular damage and poor outcome • Diuretics improve QoL and congestion, but may be associated with WRF and worse outcome J Am Coll Cardiol 2011;57:2233-41

  11. Summary Diuretic therapy Diuretic therapy Worsening renal function Improving Congestion Prognosis J Am Coll Cardiol 2011;57:2233-41

  12. Aim and Hypothesis • Aim: • To investigate the effect modulation of congestion by diuretics (witdrawal and re-initiation) on markers of renal and tubular function in heart failure. • Hypothesis: • Diuretic therapy reduces central and renal venous pressure, improving GFR and tubulo-interstitial damage J Am Coll Cardiol 2011;57:2233-41

  13. Methods • Prospective cohort, Birmingham, UK • Patientpopulation (N = 30): • chronicsystolicheart failure (EF < 40%) • presumedeuvolemic state • on oral loop diureticregimen (Furosemide 40 / 80 mg ) • treatedaccordingtoguidelines J Am Coll Cardiol 2011;57:2233-41

  14. Methods 7 day Study Protocol J Am Coll Cardiol 2011;57:2233-41

  15. Methods • Outcomemeasures: • - Markers of Volume overload: ANP, BNP • - Markers of glomerularfiltration: serum creatinine • - Markers of tubulo-interstitialdamage (urine): • - KIM-1 (KidneyInjury Molecule 1) • - NAG (N-acetyl-beta-D-glucosaminidase) • - NGAL (NeutrophilGelatinaseAssociatedLipocalin) J Am Coll Cardiol 2011;57:2233-41

  16. Baseline Characteristics J Am Coll Cardiol 2011;57:2233-41

  17. Baseline Characteristics J Am Coll Cardiol 2011;57:2233-41

  18. Results J Am Coll Cardiol 2011;57:2233-41

  19. Results: Creatinine Mean ± SEMs are presented * P < 0.001 vs Day 1, baseline, † P < 0.05 vs Day 4 J Am Coll Cardiol 2011;57:2233-41

  20. Results: ANP/BNP Diuretic withdrawal and reinitiation * P < 0.01 vs baseline, † P < 0.05 vs baseline, # P < 0.05 vs Day 4 J Am Coll Cardiol 2011;57:2233-41

  21. Results: ANP/BNP Mean ± SEMs are presented. * P < 0.01 vs Day 1, baseline, † P < 0.05 vs Day 1, # P < 0.05 vs Day 4 J Am Coll Cardiol 2011;57:2233-41

  22. Results: Tubular markers Diuretic withdrawal Median and IQRs are presented. * P < 0.01, † P = 0.075 vs Day 1, baseline J Am Coll Cardiol 2011;57:2233-41

  23. Results: Tubular markers Diuretic withdrawal J Am Coll Cardiol 2011;57:2233-41

  24. Results: Tubular markers Diuretic Reinitiation Median and IQRs are presented. * P < 0.05 vs Day 4, 0 hours J Am Coll Cardiol 2011;57:2233-41

  25. Results: Tubular markers Diuretic Reinitiation J Am Coll Cardiol 2011;57:2233-41

  26. Results: Tubular markers Absolute Changes Diuretic Withdrawal Diuretic Reinitiation J Am Coll Cardiol 2011;57:2233-41

  27. Results: correlations • No significant correlation between changes in Natriuretic Peptides and changes in tubular damage markers • No significant correlations between changes in tubular markers and changes in serum creatinine J Am Coll Cardiol 2011;57:2233-41

  28. Results: findings • Diuretic withdrawal lead to: • an increase in ANP apparent after 4 hours • an increase in BNP apparent at day 4 • no significant alterations in serum creatinine • an increase in urinary KIM-1, apparant after 8 hours, which was sustained through day 4 • an increase in urinary NAG, apparent at day 3 • no change in either serum or urinary NGAL levels J Am Coll Cardiol 2011;57:2233-41

  29. Results: findings • Diuretic reinitiation lead to: • no decrease in ANP, but further increase • a decrease in BNP to baseline levels • no change in serum creatinine • a decrease in urinary KIM-1, apparant after 4 hours, which was sustained through day 7 • a decrease in urinary NAG, apparent after 8 hours, and which was sustained through day 7 • no change in either serum or urinary NGAL levels J Am Coll Cardiol 2011;57:2233-41

  30. Conclusion • Diuretic withdrawal leads to increased markers of volume overload and this was paralleled by an increase in urinary levels of markers of tubular damage, especially KIM-1 and NAG • Reinitiation of diuretics leads to reduction of both urinary KIM-1 and NGAL • There was no effect of diuretic manipulation on NGAL levels J Am Coll Cardiol 2011;57:2233-41

  31. Discussion • Modulation of volume (overload), even in HF patientswith a presumedeuvolemic state caused changes in tubulardamage markers, but not serum creatinine • These markers are much more sensitive to small changes in glomerular and tubularfunction/integrity, and maytherefore serve as early and specific markers of impairedrenalfunction. • On the other hand, elevatedtubular markers alsoindicatetubulo-interstitialdamage. J Am Coll Cardiol 2011;57:2233-41

  32. Discussion • How does diuretictherapyinfluence (renal) tubularfunction? • 2 Hypotheses: • (renal) Congestioncausestubulardamage and renalinterstitialfibrosis in heartfailue. Diuretics directlyimprovecongestion, thereforetubularfunction • Diuretic therapydecreasesworkload of the proximaltubule (lesssaltretained), whichinducesfavourableconditions: lessoxygenconsumption, decreasedrenalhypoxia. J Am Coll Cardiol 2011;57:2233-41

  33. Discussion • Future studies are needed to: • Investigate placebo-controlledeffects of diuretics on renalfunction and outcome • Identify high risk individualsfor the development of WRF, usingspecificnewtubular markers, such as KIM-1 / NAG/NGAL • Investigate the ability of these new markers to monitor and guide therapy in heart failure, especiallydiuretictherapy J Am Coll Cardiol 2011;57:2233-41

  34. Acknowledgments Birmingham, UK: Dr. R MacFadyen Dr. JMNK Chuen Dr. GYH Lip Dr. L Fransisco Groningen, NL: Prof. dr. DJ van Veldhuisen Prof. dr. HL Hillege Prof. dr. G Navis Prof. dr. AA Voors W. Van Oeveren J Am Coll Cardiol 2011;57:2233-41

More Related